Figure 1

10

$$R = CH_2OTBS$$
 $(CH_2)_3OTBDPS$
 $R = CH_2OTBS$
 $(CH_2)_3OTBDPS$
 $(CH_2)_3OTBDPS$

Figure 3(A)

Figure 4

50% for three steps

^{*17} steps from known starting materials vs. 27 steps for aldol macrocyclization

Convergent strategy for a total synthesis of epothilone A (1).

The glycal cyclopropane solvolysis strategy for the introduction of geminal methyl groups.

Enantioselective synthesis of compound 15B

Construction of epothilone model systems $20^8,\,21^8$, and 22^8 by ring-closing olefin metathesis




Figure 10




Figure 11

Figure 12

TMSO R₁ +
$$\frac{diene-aidehyde}{cytdlocondensation}$$
 + $\frac{diene-aidehyde}{cytdlocondensation}$ + $\frac{R_2}{R_1}$ + $\frac{R_1}{R_2}$ + $\frac{R_2}{R_1}$ + $\frac{A_1}{R_2}$ + $\frac{A_2}{R_1}$ + $\frac{A_2}{R_2}$ + $\frac{A_1}{R_1}$ + $\frac{A_2}{R_2}$ + $\frac{A_2}{R_1}$ + $\frac{A_2}{R_2}$ + $\frac{A_1}{R_1}$ + $\frac{A_2}{R_2}$ + $\frac{A_2}{R_1}$ + $\frac{A_2}{R_1}$ + $\frac{A_2}{R_2}$ + $\frac{A_2}{R_1}$ + $\frac{A_2}{R_1}$

Figure 13




Figure 14




Figure 15

Figure 16

Figure 18

Figure 19

24D

G.

FIGURE 27




FIGURE 28




FIGURE 29




FIGURE 30




FIGURE 31

.





FIGURE 32






FIGURE 34





FIGURE 35






FIGURE 37






Figure 38

Fig. 42(B)










Fig. 44(B









Fig. 46


Fig. 47



.

1 5034 3,1057 1,1181 2,1181 2,1181 2,1052 1,1181 2630 I 1670.0 5570.1 S 1294 1.0572 400 MHZ, cdc13, rt, 1.0374 ZF66 0 1 0000 . 5

Fig. 50



. ;

...

...

FIG. 1A

F1G. 12B

R= H; epothilone A R= CH3: epothilone B

I A: taxol TM

FIG. 2


 $R = CH_2OH$


$$(CH_2)_3OH$$


 $\mathbf{R} = \mathbf{CH_2OH}$ $(\mathbf{CH_2)_3OH}$

e,

FIG 3B









F.

F16. 3E

F1G. 4A



OTPS - 20:R = CH(0Me)₂ -21:R = CH0 FIG. 4B




F1G. 5

50% for three steps

FIG. 6A

FIG. 6B



 * 17 steps from known starting materials vs.27 steps for aldol macrocyclization

cis epoxide (epothilone A)

trans epoxide (epothilone analog)

;

ሯ

Convergent strategy for a total synthesis of epothilone A (1).

P=unspecified protecting group

Ę.

1




FIG. 10





FIG. 11



ņ,

IDOOKSY1 IZCOMO1

F16. 13

F1G. 14A






FIG. 14B



F1G. 15



Et20,-78°C OTPS imidazol, DMF LAH TPSCI TiCl4,CH2Cl2,-78°C SH(CH2)₃SH TiCl4,CH₂Cl₂


F1G. 18A

I.TBSOT f 2.DDQ 3.Wittig olefination

В

F16. 18B

F16. 19A




28/76 $R^1 = R^2 = H$; $C_8 - desmethyl - epothilone A (3D)$ 9 R1=H, R2 = Me; epothilone A F1G. 20A R1=R2= Me; epothilone B TBS = Sit - bu Me2 80 q, b 9D # R=t-buty ▼10D#R=TBS FIG. 19C FIG. 20B

FIG. 21

F1G. 22 A

FIG. 22B

F16. 22C




F16. 23A

FIG. 23B

F16. 23C

FIG. 24A



minor product from suzuki coupling reaction

HF-pyridine, THF 95% 19D

FIG. 25A




FIG. 25B





FIG. 25C

F16. 25D



F1G. 26A

866

FIG. 26B

R = H, F, CF₃
R=H is the only compound completed, F and CF₃ are nearly completed

F16, 26C

22D (R = H)


F1G. 27A

FIG. 27B

60%, Z/E 2:1


F16. 27C


FIG. 28A





7

FIG. 28B














0.5

5

5.0

2.5


3.0


5.0


6.0 5.5

6.5

2.0









0.0 0.5 - 0: <u>.</u> 50. 2.5 3.0 3.5 0.4 4.5 50 5.5 6.0 6.5

Ŷ,



0.0 0.5 0 2.5 3.0 3.5 4.5 5.0 5.5 6.0 6.5 2.0





0.0	
0.5	
-2:	
-5:	
2.0	
2.5	
3.0	
3.5	
4.0	
4.5	
5.0	
5.5	
6.0	
6.5	
102	٠




FIG. 39A

F1G. 39B

FIG. 40A desoxyepothilone B 10 (0.0095) [0.017] 9 (0.00017) [0.0012] synthetic epothilone B 8 (0.00044) [0.0026]

FIG. 40B

FIG. 41A

FIG. 41B

FIG. 42B

F16. 42C

F1G. 42D




FIG. 42E

64/76 FIG. **43**A







FIG. 43B









F16. 44B



68/76

FIG. 45A





70/76

FIG. 46








FIG. 47

















0.0 . 으 2.5 3.0 3.5 6.0 6.5 2.0